Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.

As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.